News | August 08, 2021
Cipla posts net profit at Rs 715 crores
India business contributes to a stellar performance
India business contributes to a stellar performance
The transaction is expected to close in the Q4FY22
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
This robust growth has come despite the raging pandemic for most part of the quarter
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
Advances deployment of mRNA technology across vaccines and therapeutics development
In the agreement, Marcor, an Azelis Americas company, will distribute the SPI Pharma product lines in the United States, and Azelis Canada Pharma Division will be responsible for the Canadian marketplace
He will be stationed at the company HQ in Bengaluru, India
CDSCO to fast-track trials and approval for COVID19 vaccine
Centre at Sree Chitra Tirunal Institute for Medical Sciences and Technology
Subscribe To Our Newsletter & Stay Updated
